On Friday, Feb. 28, 2025, Cathie Wooden’s Ark Make investments made some notable trades. Probably the most distinguished amongst these have been the purchases of Archer Aviation Inc ACHR, Recursion Prescribed drugs Inc RXRX, Tempus AI Inc TEM, and Iridium Communications Inc IRDM.
Alternatively, Ark Make investments determined to dump shares of Twist Bioscience Corp TWST, Adyen NV ADYEY, Accolade Inc ACCD, and Actual Sciences Corp EXAS.
The ACHR Commerce
Ark Make investments bought a major variety of shares in Archer Aviation Inc throughout three of its ETFs. The ARK Innovation ETF ARKK purchased 360,583 shares, the ARK Autonomous Know-how & Robotics ETF ARKQ acquired 54,699 shares, and the ARK Area Exploration & Innovation ETF ARKX added 17,322 shares.
Based mostly on the closing worth of $8.88 on Friday, the full worth of those trades is roughly $3.8 million.
The RXRX and TEM Trades
Ark Make investments additionally confirmed a robust curiosity in Recursion Prescribed drugs Inc and Tempus AI Inc. Ark Make investments beforehand bought a considerable variety of shares in Tempus AI regardless of the corporate’s inventory falling after reporting combined fourth-quarter outcomes.
Ark Make investments’s ARK Genomic Revolution ETF ARKG purchased 268,467 shares of Recursion Prescribed drugs and 32,467 shares of Tempus AI.
The ARK Innovation ETF acquired 384,956 shares of Recursion Prescribed drugs and 49,250 shares of Tempus AI.
Given the closing costs of $56.18 for Tempus AI and $7.51 for Recursion Prescribed drugs, the full worth of those trades is $36.7 million and $0.61 million, respectively.
The IRDM, TWST, ADYEY, ACCD, and EXAS Trades
Ark Make investments’s ARK Innovation ETF purchased 73,659 shares of Iridium Communications Inc, whereas promoting 65,290 shares of Twist Bioscience Corp.
The ARK Subsequent Era Web ETF offered a small variety of shares (52) of Adyen NV.
The ARK Genomic Revolution ETF offered 80,270 shares of Actual Sciences Corp and a minor amount (232) of Accolade Inc shares.
Learn Subsequent:
Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and revealed by Benzinga editors.
Picture through Ark Make investments
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
